Vaccine partners Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) released information today that provides new evidence that their COVID-19 vaccine is effective against the B.1.1.7 variant that was initially detected in the United Kingdom and is believed to be more contagious than the original strain of the coronavirus. Pfizer and BioNTech conducted a laboratory study in which blood serum from trial subjects who had received the companies’ BNT162b2 vaccine was exposed to pseudoviruses bearing either the spike protein of the original Wuhan strain or that of the B.1.1.7 variant. In the study, investigators tested sera from 16 trial subjects — eight from adults between 18 and 55 years old and eight from older subjects.

Leave a Reply

Your email address will not be published. Required fields are marked *